Novel sublingual wafer platform technology
Repurposed drugs have superior delivery and absorption, improved patient compliance and renewed market exclusivity.
Approved active compounds have established safety and toxicity profiles. We reposition these actives for new indications with unmet medical needs. Leveraging on expedited pathways like FDA 505(b)(2), development risks and costs are lowered with faster speed to market.
We develop innovative therapies that improve the quality of life for patients with pain, chronic diseases and debilitating conditions.
We have a robust pipeline of CNS products that are being developed and clinically evaluated. Our portfolio includes Wafermine (sublingual ketamine) for pain and depression, BnoX (sublingual buprenorphine) for pain, and Wafesil (sublingual sildenafil) for erectile dysfunction.
Our revolutionary sublingual cannabis wafers for medicinal and supplement use have been awarded “CBD Product of the Year 2020” by the Australian Cannabis Awards.
Our lead product under development is a sublingual racemic ketamine wafer which is being evaluated for the treatment of acute moderate to severe pain.
Phase 3-ready, positive results in Phase 2b
Fully integrated from R&D, manufacturing, regulatory affairs to sales.
End-to-end service, faster speed to market
Fully licensed, TGA-compliant cGMP facility.
Proprietary freeze-drying process supported by highly trained professionals and specialised equipment.
iX Biopharma Ltd. has reported its first half results for the financial year as of 31 December 2023.
More information can be found here.
iX Biopharma introduces MeltMed, a new wellness brand in the United States.
The news release can be found here.